HomeOpen Access NewsDiseases & Conditions

Diseases & Conditions

Global measles cases surge in 2023: What does the future hold?

In 2023, the world saw an increase in measles cases, with an estimated 10.3 million people infected, showing a 20% rise from the previous year.

Learning from COVID-19: Can we prepare for future epidemics?

Margaret Heffernan, Author of Uncharted, shares her thoughts about how AI, big data and forecasting might not be the solution to the coronavirus, and how society should really be preparing itself for more inevitable epidemics.

Graph theory in the study of Alzheimer’s disease progression

María J. Peláez1, Prashant Dogra1, Zhihui Wang1, Vittorio Cristini1 1Mathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030, USA.

Soluble circulating cytokine receptors in chronic inflammatory lung diseases

Michael Roth discusses soluble circulating cytokine receptors in chronic inflammatory lung diseases, which he describes as the under-estimated regulators of inflammation and remodelling.

Europe deserves more and better research & innovation in cardiovascular disease

Prof Lina Badimon, Chair, ESC Advocacy Committee 2018-2020 Director, Cardiovascular Program (ICCC) – IR, Hospital de la Santa Crue I Sant Pau, argues that Europe deserves more and better research & innovation in cardiovascular disease.

A focus on rare disease: Paroxysmal nocturnal haemoglobinuria (PNH)

Maria Piggin, Chair of PNH Support tells us about the rare disease, paroxysmal nocturnal haemoglobinuria (PNH) and in this area, collaborations for change.

Leading a normal life with a Noonan Syndrome child: Benji Ballard’s story

Katie Ballard, a trustee of the Noonan Syndrome Association, shares her story of son Benjamin after receiving a life-changing diagnosis of Noonan Syndrome and cardiomyopathy.

Pulmonary rehabilitation: Changing the lives of patients with lung disease

Jessica Eagelton, co-chair of the Taskforce for lung Health Pulmonary Rehabilitation working group, discusses Pulmonary rehabilitation: a drug-free treatment that is changing the lives of people with lung disease.

European Commission announces €232 million aid package to tackle COVID-19

In a bid to tackle the recent outbreak of COVID-19 the European Commission has announced a new aid package worth €232 million.

Global Food Research: Will front-of-the-package warning labels change our eating habits?

The Global Food Research Program shares their perspective on targeting ultra-processed foods with front-of-the-package warning labels, which is the only impactful approach.

The 2010s: Advances witnessed in muscle-wasting conditions research

Kate Adcock, Director of Research and Innovation, Muscular Dystrophy UK, charts the advances over the past decade in muscle-wasting conditions research.

Assessment and surveillance to mitigate infectious diseases in Africa

Cecilia Van Cauwenberghe from Frost & Sullivan’s TechVision Group, gives a call to action when it comes to assessment and surveillance to mitigate the impact of infectious diseases in Africa.

Lung disease: A focus on idiopathic pulmonary fibrosis

Stephen C Clark, from Newcastle upon Tyne Hospitals NHS Foundation Trust and University of Northumbria in the UK explains idiopathic pulmonary fibrosis, a type of lung disease.

Government pledges £20 million to develop new coronavirus vaccine

The Government has today pledged £20 million to develop a new coronavirus vaccine following concerns over the ongoing outbreak in China.

Multiple cases of coronavirus confirmed in the UK

Chief Medical Officer, Professor Chris Whitty has announced that two cases of coronavirus have been confirmed in England.

Controlling and preventing diseases: A focus on traumatic brain injury

The work of the Centers for Disease Control and Prevention, within the U.S. Department of Health & Human Services is examined here, with a special focus on traumatic brain injury.

Fine dust air pollution (PM2.5) as a cause of chronic inflammatory lung diseases?

Michael Roth, Research Group Leader at University Hospital Basel asks if fine dust air pollution (PM2.5) is a cause of chronic inflammatory lung diseases and provides a most engaging response.

Advertisements


Latest Academic Articles

The latest academic articles from key research stakeholders